PDF of Trial CTRI Website URL -
|
|
- Christopher Beasley
- 5 years ago
- Views:
Transcription
1 Clinical Trial Details (PDF Generation Date :- Sun, 17 Mar :11:08 GMT) CTRI Number CTRI/2010/091/ [Registered on: 11/08/2010] - Last Modified On 14/03/2013 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study Scientific Title of Study No Interventional Drug Single Arm Trial A clinical trial to study the effects of FDC of Cephalexin Extended Release and Clavulanate Potassium Tablets in patients with upper respiratory tract infections. "Efficacy, Safety and Tolerability of Fixed Dose Cbination of Cephalexin Extended Release and Clavulanate Potassium Tablets in the Treatment of Upper Respiratory Tract Infections" Secondary IDs if Any Secondary ID Identifier Details of Principal Investigator or overall Trial Coordinator (multi-center study) Details Contact Person (Scientific Query) Details Contact Person (Public Query) RCEPCL Designation Affiliation Protocol Number Details of Principal Investigator Amit Nasa Project Leader Phone Fax Designation Affiliation Project Leader, Ranbaxy Laboratories Ltd. Plot No.77-B, Sector-18, IFFCO Road Gurgaon HARYANA amit.nasa@ranbaxy.c Details Contact Person (Scientific Query) Sanjay K Sharma Associate Director Phone Fax Designation Affiliation Medical Monitor, Ranbaxy Laboratories Ltd. Plot No.77-B, Sector-18, IFFCO Road Gurgaon HARYANA ashish.dhabre@ranbaxy.c Details Contact Person (Public Query) Amit Nasa Project Leader Project Leader, Ranbaxy Laboratories Ltd Plot No.77-B, Sector-18, IFFCO Road Gurgaon HARYANA page 1 / 6
2 Source of Monetary or Material Support Primary Sponsor Details of Secondary Sponsor Countries of Recruitment Sites of Study Phone Fax Source of Monetary or Material Support > Ranbaxy Laboratories Ltd., Plot No. 77-B, Sector 18, Gurgaon , Haryana Type of Sponsor Nil List of Countries of Principal Investigator Dr. Anand Patel Primary Sponsor Details MACR,, Ltd, Plot No. 77-B, Sector-18, IFFCO Road, Gurgaon , Haryana Pharmaceutical industry-global Nil of Site Site Phone/Fax/ Anand Multispeciality Hospital Anand Multispeciality Hospital,Sundervan Cplex, B Tower, B/H. I.T.I Vadodara GUJARAT Dr. Akash Lataru Balki Chest Care Hospital Chest Care Hospital,Sakkardhara SQ, Umred Road Nagpur Dr. Mukesh Jain Dr. Mukesh Jain Clinic Dr. Mukesh Jain Clinic,70/70, Madhyam Marg, Mansarovar Jaipur RAJASTHAN Dr. Sonia K Dalal Kalyan Polyclinic Kalyan Polyclinic, , Shree Hari Corner,RC Dutt road, Alkapuri Vadodara GUJARAT Dr. Puneet Rijhwani Mahatma Gandhi Medical College & Hospital Mahatma Gandhi Medical College & Hospital,Sitapura Tonk Road Jaipur RAJASTHAN Dr. Aniket Joshi OM Clinic OM Clinic, 1 Niratinath soc,mukund Nagar Pune Dr. Yogesh Kadam Poona Diabetes Center Office No. 8, 1st Floor, Bharat Arcade,Gen. Thimmaya (0265) anandmultispecialityhos pitals@yahoo.c akash_balki@yahoo.co m drmukesh13@yahoo.co m (0265) drsoniadalal@hotmail.c puneet284@rediffmail.c (020) acj @yahoo.c (020) drprayogk@rediffmail.c page 2 / 6
3 Details of Ethics Cmittee Dr. Sandeep Saboo Dr. Manish Kumar Jain Saboo Hospital and Research Center Shwaas Center, Navkar Hospital Road Pune Saboo Hospital and Research Center, /27, Begum Bazar Hyderabad ANDHRA PRADESH G-11, Shubham Apartment,,Central Spine, Vidhyadharnaga r Jaipur RAJASTHAN Dr. Sunil Singhvi Singhvi Clinic Singhvi Clinic, No.127,Mint Street, Sowcarpet Chennai TAMIL NADU Dr. Vivek Gupta Suretech Hospital and Research Centre Suretech Hospital and Research Centre,R.P. Banerjee Marg, Dhantoli Nagpur ffmail.c , nil ail.c (044) of Cmittee Approval Status Date of Approval Is Independent Ethics Cmittee? Chennai Ethical Cmittee, Chennai (for Dr Sunil Singhvi) Ethics cmittee of Biniwale clinic, Pune (for Dr Aniket Joshi) Ethics cmittee of Biniwale clinic, Pune (for Dr Yogesh Kadam) G. G. Memorial Ethical Cmittee For Human Research, Jaipur Approved 17/11/2010 Yes Approved 31/05/2010 Yes Approved 31/05/2010 Yes Approved 21/04/2010 No Institutional Ethics Cmittee, Mahatama Gandhi Medical College and Hospital, Jaipur Approved 20/09/2010 No Maanav Health Foundation Independent Ethics Cmittee, vadodara (for Dr Anand Patel) Maanav Health Foundation Independent Ethics Cmittee, Vadodara (for Dr Sonia Dalal) Midcity Independent Ethics Cmittee, Nagpur (for Dr Akash Approved 27/05/2010 Yes Approved 27/05/2010 Yes Approved 06/06/2010 Yes page 3 / 6
4 Regulatory Clearance Status fr DCGI Health Condition / Problems Studied Intervention / Cparator Agent Inclusion Criteria Balki) Midcity Independent Ethics Cmittee, Nagpur (for Dr Vivek Gupta) Saboo Hospital & Research Center,Independent Ethics cmittee, Hyderabad (for Dr Sandeep Saboo) Swasthya Kalyan Ethics Cmittee, Jaipur (for Dr Mukesh Jain) Status Approved 06/06/2010 Yes Approved 26/06/2010 Yes Approved 14/04/2010 Yes Date Approved/Obtained 08/04/2010 Health Type Patients Condition Upper Respiratory Tract Infections Type Details Intervention FDC of Cephalexin extended release and clavulanic potassium Cparator Agent nil nil Age Fr Age To Gender Details Year(s) Year(s) Both Inclusion Criteria Cephalexin ER 375mg and clavulanate potassium 125 mg tablets orally, twice daily for 10 days Subjects of either sex aged more then or equal to 12 years and weighing more then or equal to 40 kg suffering fr upper respiratory tract infection (with onset of infection less then 7 days) with diagnosis of acute pharyngitis and/or tonsillitis. Diagnosis will be made on the basis of clinical and microbiological criteria Clinical criteria Clinical diagnosis will be based on following signs and sympts: sore and scratchy throat and/or pain on swallowing along with any two of following: Tonsillar and/or pharyngeal exudates, tonsillar and/or pharyngeal erythema, fever [temp. more then or equal to 38C/ & more then or equal to 100.4F (or history of fever treated with antipyretics)], uvular edema, tender cervical adenopathy. Microbiological criteria A positive pre-treatment throat swab culture defined as identification of at least one of the following respiratory pathogens: Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Moraxella (Branhamella) catarrhalis, Staphylococcus aureus. Note: Treatment will be initiated before the results of throat swab culture are available. However,when these results bece available (within 3-5 days of enrollment), suitability of subject for inclusion will be reviewed. Subjects with sterile culture or culture not positive for respiratory pathogens as defined above will be withdrawn fr the study. Subjects showing clinical improvement with isolate (s) resistant to study medication will be allowed to continue at the page 4 / 6
5 Exclusion Criteria Method of Generating Rand Sequence Method of Concealment Blinding/Masking Details discretion of the investigator. Subjects who have persistence or worsening of signs and sympts or appearance of new signs and sympts after 3 days of treatment will be withdrawn fr the study Exclusion Criteria 1.Subjects with history of hypersensitivity to cephalexin, other cephalosporins, penicillins, clavulanate potassium or other betalactam class of antibiotics or any of the excipients* of study formulation 2.Subjects requiring hospitalization or parenteral antibiotic treatment 3.Subjects who have received antibiotic treatment for >/= 24 hours during the 72 hours prior to enrollment in the study (unless treatment failure was documented) 4.Infection of the deep tissues of the upper respiratory tract (e.g. epiglottitis, retropharyngeal or buccal cellulitis or abscess of the retropharynx/ tonsil or peritonsillar area) or of the suprapharyngeal respiratory tract and its connecting structures (e.g. sinusitis, otitis media or orbital/periorbital cellulitis) 5.Subjects with a concitant infection that needs an additional anti-microbial agent or which in the opinion of the investigator could preclude evaluation of response to study medication 6.Subjects with renal failure who are on hemodialysis, peritoneal dialysis, plasmapheresis or hemoperfusion 7.Subjects who are unable to take oral medication 8.Subjects with clinically significant cardiovascular, hematological (including subjects with bleeding diathesis, on anticoagulant therapy or with vitamin K deficiency), renal, hepatic, endocrinal, pulmonary, urogenital, gastrointestinal, progressive neurological illness (including subjects with history of epilepsy) or psychiatric illness or any other medical condition that might put the subject at greater risk during study participation 9.Pregnant or breast feeding wen or wen of child-bearing potential not using medically acceptable methods of contraception or wen with positive urine pregnancy test (UPT) at screening 10.Subjects with history of drug or alcohol abuse 11.Subjects unwilling or unable to cply with the study procedures 12.Subjects who have participated in another investigational study in the previous 3 months prior to enrollment in this study 13.Subjects on chronic immunosuppressive therapy or diagnosis of acquired immunodeficiency syndre (AIDS) or hepatitis 14.Subjects with SGOT/AST or SGPT/ALT >3.0 times upper limit of normal (ULN) or alkaline phosphatase >2.0 times ULN or serum bilirubin >1.5 times ULN or TLC <4000/mm3 or creatinine clearance of <30 ml/ min (estimated fr serum creatinine using the Cockcroft-Gault formula**) *Microcrystalline cellulose; sodium starch glycolate; colloidal Anhydrous silica; magnesium stearate; hyprellose; hydroxypropyl cellulose; talc; opadry; polyethylene glycol **Creatinine clearance (CLcr) = 140? age (years) x weight (kg) 72 x serum creatinine (mg/dl) For female subjects: Final value as per above formula should be multiplied by 0.85 Primary Outce Outce Timepoints Investigator assessed clinical outce in clinically evaluable subjects At test-of-cure visit (4-8 days after end of treatment) Secondary Outce Outce Timepoints Microbiological outce in all microbiologically evaluable subjects At test-of-cure visit (4-8 days after end of treatment) page 5 / 6
6 Powered by TCPDF ( Target Sample Size Phase of Trial Phase 3 Date of First Enrollment () Date of First Enrollment (Global) Estimated Duration of Trial Recruitment Status of Trial (Global) Recruitment Status of Trial () Publication Details Brief Summary Total Sample Size=100 Sample Size fr =100 27/01/2011 No Date Specified Years=0 Months=6 Days=0 Cpleted This study is an open-label, non-cparative study with an objective to cpare the Efficacy, Safety and Tolerability of Fixed Dose Cbination of Cephalexin Extended Release and Clavulanate Potassium Tablets in the Treatment of Upper Respiratory Tract Infections. The study is to be conducted at 10 centres all over. The primary outce is Investigator assessed clinical outce in clinically evaluable subjects at test-of-cure visit (4-8 days after end of treatment) and secondary outce is Microbiological outce in all microbiologically evaluable subjects at test-of-cure visit (4-8 days after end of treatment). page 6 / 6
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Mon, 11 Mar 2019 09:06:55 GMT) CTRI Number CTRI/2009/091/000725 [Registered on: 15/09/2009] - Last Modified On Post Graduate Thesis Type of Trial Type of
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 10 Mar 2019 06:52:14 GMT) CTRI Number Last Modified On 29/07/2016 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationPATIENT INFORMATION LEAFLET DYNA CEFPODOXIME 100 mg / DYNA CEFPODOXIME SUSPENSION:
SCHEDULING STATUS S4 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: DYNA CEFPODOXIME 100 mg (film coated tablet) DYNA CEFPODOXIME SUSPENSION (powder for oral suspension) Please read this leaflet carefully
More informationPrescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children
Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children Prescribing Antimicrobials for Common Illnesses When treating common illnesses such as ear infections and strep throat,
More informationWorkshop on the use of antibiotics. Dr Rosemary Ikram FRCPA Consultant Clinical Microbiologist
Workshop on the use of antibiotics. Dr Rosemary Ikram FRCPA Consultant Clinical Microbiologist Declaration of affiliations. Working with: BPAC, DHBSS laboratory schedule group, IANZ, Pharmacy Brands (UTI
More information11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1
Disclosures Selecting Antimicrobials for Common Infections in Children FMR-Contemporary Pediatrics 11/2016 Sean McTigue, MD Assistant Professor of Pediatrics, Pediatric Infectious Diseases Medical Director
More informationSrirupa Das, Associate Director, Medical Affairs, Tushar Fegade, Manager, Clinical Research Abbott Healthcare Private Limited, Mumbai.
Indian Medical Gazette JUNE 2015 225 Comparative A Randomized, Open Label, Prospective, Comparative Evaluating the Efficacy and Safety of Fixed Dose Combination of Cefpodoxime 200 Mg + Clavulanic Acid
More information$100 $200 $300 $400 $500
Skin is In Runny Noses Got to go! Hear no evil It s in the Lungs $100 $100 $100 $100 $100 $200 $200 $200 $200 $200 $300 $300 $300 $300 $300 $400 $400 $400 $400 $400 $500 $500 $500 $500 $500 Double Jeopardy
More informationVolume. December Infection. Notes. length of. cases as 90% 1 week. tonsillitis. First Line. sore throat / daily for 5 days. quinsy >4000.
Volume 8; Number 22 LINCOLNSHIRE GUIDELINES FOR THE TREATMENT OF COMMONLYY OCCURRING INFECTIONS IN PRIMARY CARE: WINTER 2014/15 In this issue of the PACE Bulletin we present an update of our Guidelines
More informationShort Course Antibiotic Therapy of Streptococcal Pharyngitis: Comparison of Clarithromycin with Amoxicillin/ Clavulanate and Cefuroxime Axetil
Short Course Antibiotic Therapy of Streptococcal Pharyngitis: Comparison of Clarithromycin with Amoxicillin/ Clavulanate and Cefuroxime Axetil D. Adam, MD PhD, Munich, Germany H. Scholz, MD PhD, Berlin,
More information- { PAGE } - GOVERNMENT OF RAJASTHAN DIRECTORATE MEDICAL, HEALTH F.W. SERVICES RAJASTHAN, JAIPUR
Tender Catelogue for Part-A (Drugs & Medicines) Section-B (Harmons and Antihormones, Antiparkinsonism drugs, Drugs affecting the Blood, Blood Products and Plasma Substitutes, Cardiovascular drugs, Dermatological
More informationVolume 2; Number 16 October 2008
Volume 2; Number 16 October 2008 What s new this month NHS Lincolnshire have launched a public information campaign designed to raise public awareness of the risks associated with the inappropriate use
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationCLINICAL USE OF BETA-LACTAMS
CLINICAL USE OF BETA-LACTAMS Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu WHY IS INFECTIOUS DISEASE PHARMACOTHERAPY SO CONFUSING? Microbial
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rycarfa 100 mg tablets for dogs (BE, DE, ES, FR, IE, IT, NL, PT, UK) Rycarfa vet 100 mg tablets for dogs (DK, FI) Carprox
More informationPrepared: August Review: July Common Infections. A Medicines Optimisation Antibiotic Prescribing Guide.
Prepared: August 2013 Review: July 2014 Common Infections. A Medicines Optimisation Antibiotic Prescribing Guide. Contents Page: Page No Why do we want to review antibiotics? 2 What do NICE say? 3 Acute
More informationStaphylex Flucloxacillin (as sodium) PRODUCT INFORMATION
Staphylex Flucloxacillin (as sodium) PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredient : Flucloxacillin sodium Chemical name : 3-(2'-chloro-6'-fluorophenyl)-5-methyl-4-isoxazolylpenicillin monohydrate
More informationSafety of an Out-Patient Intravenous Antibiotics Programme
Safety of an Out-Patient Intravenous Antibiotics Programme Chan VL, Tang ESK, Leung WS, Wong L, Cheung PS, Chu CM Department of Medicine & Geriatrics United Christian Hospital Outpatient Parental Antimicrobial
More informationAppropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
More informationPart II SUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 25 mg Clindamycin (as Clindamycin Hydrochloride)
Clindacyl 25mg Tablets Vm 08007/4104 Part II SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CLINDACYL 25 MG TABLETS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT RONAXAN 20mg Tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance : Doxycycline (as doxycycline
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KEFLEX safely and effectively. See full prescribing information for KEFLEX KEFLEX (cephalexin) capsules,
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cephacare flavour 50 mg tablets for cats and dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metrobactin 500 mg tablets for dogs and cats (AT, BE, BG, CY, CZ, DE, EL, ES, FR, HR, HU, IE, IT, LU, NL, PL, PT, RO, SI,
More informationClinical Practice Standard
Clinical Practice Standard 1-20-6-1-010 TITLE: INTRAVENOUS TO ORAL CONVERSION FOR ANTIMICROBIALS A printed copy of this document may not reflect the current, electronic version on OurNH. APPLICABILITY:
More information1. WHAT CO-AMOXICLAV TABLETS IS AND WHAT IT IS USED FOR
Package leaflet: Information for the patient Co-amoxiclav 250 mg/125 mg film-coated tablets amoxicillin/clavulanic acid Read all of this leaflet carefully before you start taking this medicine, because
More informationDelayed Prescribing for Minor Infections Resource Pack for Prescribers
Delayed Prescribing for Minor Infections Resource Pack for Prescribers Background: Antibiotic resistance is an alarming threat to modern healthcare, and infectious illness remains a major global threat
More informationCopy in the header and footer will not appear on the final printed label LAB0042 Prepared: 28/02/01 SYRINGE LABEL
SYRINGE LABEL PRESCRIPTION ANIMAL REMEDY FOR ANIMAL TREATMENT ONLY VibraVet* 100 PASTE For Cats and Dogs 100 mg/g DOXYCYCLINE as monohydrate Infopest Verified Antibiotic READ LEAFLET BEFORE USE 2.5 g 2.0
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Carprodyl Quadri 120 mg chewable tablets for dogs Carprodyl vet. 120 mg chewable tablets for dogs (FI, SE, DK) 2. QUALITATIVE
More informationAntibiotics & Common Infections: Stewardship, Effectiveness, Safety & Clinical Pearls. Welcome We will begin shortly.
Antibiotics & Common Infections: Stewardship, Effectiveness, Safety & Clinical Pearls Welcome We will begin shortly. The Canadian Pharmacists Association is pleased to be collaborating with the following
More informationAmoxicillin 875 Mg Twice A Day For Strep Throat
Amoxicillin 875 Mg Twice A Day For Strep Throat amoxicillin 500mg 3 times a day for 7 days amoxicillin rx for dental infection amoxicillin 125mg 5ml ulotka amoxicillin 500mg 4 times a day is 500mg of amoxicillin
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICATION PATIENT MEDICATION INFORMATION. Moxifloxacin tablets (as moxifloxacin hydrochloride)
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICATION PATIENT MEDICATION INFORMATION Pr Sandoz Moxifloxacin Moxifloxacin tablets (as moxifloxacin hydrochloride) Read this carefully before you start taking
More informationReduce the risk of recurrence Clear bacterial infections fast and thoroughly
Reduce the risk of recurrence Clear bacterial infections fast and thoroughly Clearly advanced 140916_Print-Detailer_Englisch_V2_BAH-05-01-14-003_RZ.indd 1 23.09.14 16:59 In bacterial infections, bacteriological
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Amoxicillin 500 mg dispersible tablets Amoxicillin 750 mg dispersible tablets Amoxicillin 1000 mg dispersible tablets Amoxicillin Read all of this leaflet carefully
More informationCost high. acceptable. worst. best. acceptable. Cost low
Key words I Effect low worst acceptable Cost high Cost low acceptable best Effect high Fig. 1. Cost-Effectiveness. The best case is low cost and high efficacy. The acceptable cases are low cost and efficacy
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER Amoxicillin/Clavulanic acid Amneal 500 mg/125 mg film-coated tablets Amoxicillin/Clavulanic acid Amneal 875 mg/125 mg film-coated tablets (Amoxicillin/Clavulanic
More information2 What you need to know before you take Augmentin
Package leaflet: Information for the user Augmentin 375 mg Tablets co-amoxiclav (amoxicillin and clavulanic acid) Read all of this leaflet carefully before you start taking this medicine because it contains
More informationNew Zealand Consumer Medicine Information
New Zealand Consumer Medicine Information FLUCLOXACILLIN Flucloxacillin (as the sodium salt) 250 mg and 500 mg capsules Flucloxacillin (as the sodium salt) 125 mg/5 ml and 250 mg/5 ml powder for oral solution
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #65 (NQF 0069): Appropriate Treatment for Children with Upper Respiratory Infection (URI) National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationActive Constituent: Each tablet contains 500 mg cephalexin (as monohydrate) Contents: 12 [100, 300] Tablets
Carton (main panel) PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY KEFVET 500 mg Tablets for Dogs and Cats Active Constituent: Each tablet contains 500 mg cephalexin
More informationAMOCLAN HIKMA PHARMACEUTICALS
09-15 AMOCLAN HIKMA PHARMACEUTICALS (Amoxycillin and Clavulanic acid) ACTION Amoxicillin is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative
More informationActive Constituent: Each tablet contains 1000 mg cephalexin (as monohydrate) Contents: 8 [100, 300] Tablets
Carton (main panel) PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY KEFVET 1000 mg Tablets for Dogs and Cats Active Constituent: Each tablet contains 1000 mg cephalexin
More informationSUMMARY OF PRODUCT CHARACTERISTICS. KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats 2. QUALITATIVE
More informationChoosing the Best Antibiotic in Problem Outpatient Infectious Disease Cases
Choosing the Best Antibiotic in Problem Outpatient Infectious Disease Cases Dr. Earl Rubin Associate Professor Department of Pediatrics Division of Infectious Diseases Montreal Children s Hospital Disclosures
More informationLet me clear my throat: empiric antibiotics in
Let me clear my throat: empiric antibiotics in respiratory tract infections Alexander John Langley, MD MS MPH Goals of this talk Overuse of antibiotics is a major issue, as a result many specialist medical
More informationUnited Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS MUTUAL RECOGNITION PROCEDURE
United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT Clavudale
More informationPackage leaflet: Information for the patient. Amoxicilline/Clavulaanzuur Torrent 500 mg/125 mg filmomhulde tabletten. Amoxicillin Clavulanic acid
Package leaflet: Information for the patient Amoxicilline/Clavulaanzuur Torrent 500 mg/125 mg filmomhulde tabletten Amoxicillin Clavulanic acid Read all of this leaflet carefully before you start taking
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority
Quality ID #65 (NQF 0069): Appropriate Treatment for Children with Upper Respiratory Infection (URI) National Quality Strategy Domain: Efficiency and Cost Reduction Meaningful Measure Area: Appropriate
More informationProtocol for exit-site care and treatment of exit-site infections in peritoneal dialysis CONTROLLED DOCUMENT
CONTROLLED DOCUMENT Protocol for exit-site care and treatment of exit-site infections in peritoneal dialysis CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Guideline Clinical The purpose
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT GALLIPRANT 20 mg tablets for dogs GALLIPRANT 60 mg tablets for dogs GALLIPRANT 100 mg tablets for dogs 2. QUALITATIVE
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory. PHEXIN BD TABLETS 375 mg / 750 mg
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory PHEXIN BD TABLETS 375 mg / 750 mg Cephalexin Long Acting Tablets 375 mg/ 750 mg QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationPackage leaflet: Information for the patient. Co-amoxiclav 500 mg/125 mg film-coated tablets. amoxicillin/ clavulanic acid
Package leaflet: Information for the patient Co-amoxiclav 500 mg/125 mg film-coated tablets amoxicillin/ clavulanic acid Read all of this leaflet carefully before you start taking this medicine, because
More informationPATIENT INFORMATION LEAFLET GENTAMICIN 10MG/ML SOLUTION FOR INJECTION OR INFUSION. and GENTAMICIN 40MG/ML SOLUTION FOR INJECTION OR INFUSION
PATIENT INFORMATION LEAFLET GENTAMICIN 10MG/ML SOLUTION FOR INJECTION OR INFUSION and GENTAMICIN 40MG/ML SOLUTION FOR INJECTION OR INFUSION Read all of this leaflet carefully before you start taking this
More informationVeterinary Medicinal Product
Veterinary Medicinal Product Carprodyl Quadri 120 mg chewable tablets for dogs PART I B Pharmaceutical Form Chewable tablet Veterinary Medicinal Product Carprodyl Quadri 120mg chewable tablets for dogs
More informationThese recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.
Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 18 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CLAVUBACTIN 500/125 MG tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: Amoxicillin
More informationMetacam 1.5 mg/ml oral suspension for dogs
Metacam 1.5 mg/ml oral suspension for dogs Species:Dogs Therapeutic indication:pharmaceuticals: Neurological preparations: Analgesics, Other NSAIDs, Locomotor (including navicular and osteoarthritis) Active
More informationAnnex II. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation
Annex II Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation 1 Scientific conclusions Overall summary of the scientific evaluation of Amoxil and associated
More informationNEONATAL Point Prevalence Survey. Ward Form
Appendix 2 NEONATAL Point Prevalence Survey Ward Form Please fill in one form for each ward included in PPS Date of survey Person completing form (Auditor code) Hospital Name Department/Ward Neonatal departments
More informationRational use of antibiotic in upper respiratory tract infection (URI) and community acquired pneumonia รศ.จามร ธ รตก ลพ ศาล 23 พฤษภาคม 2550
Rational use of antibiotic in upper respiratory tract infection (URI) and community acquired pneumonia รศ.จามร ธ รตก ลพ ศาล 23 พฤษภาคม 2550 Sinusitis Upper respiratory tract infections (URI) Common cold
More informationUnited Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS MUTUAL RECOGNITION PROCEDURE
United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT Clavudale
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metrobactin 250 mg tablets for dogs and cats (AT, BE, BG, CY, CZ, DE, EL, ES, FR, HR, HU, IE, IT, LU, NL, PT, RO,
More informationPeriod of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)
Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationTherios 300 mg and 750 mg Palatable Tablets for Dogs
Ceva Animal Health Ltd Telephone: 01494 781510 Website: www.ceva.com Email: cevauk@ceva.com Therios 300 mg and 750 mg Palatable Tablets for Dogs Species: Therapeutic indication: Active ingredient: Product:
More informationAcute Pyelonephritis POAC Guideline
Acute Pyelonephritis POAC Guideline Refer full regional pathway http://aucklandregion.healthpathways.org.nz/33444 EXCLUSION CRITERIA: COMPLICATED PYELONEPHRITIS Discuss with relevant specialist for advice
More informationClavulin 125 Syrup PRODUCT INFORMATION. Description. Pharmacology
Clavulin 125 Syrup PRODUCT INFORMATION Description CLAVULIN is a combination product containing the semisynthetic antibiotic amoxycillin and the β-lactamase inhibitor, potassium clavulanate (the potassium
More informationVeterinary Medicinal Product
Veterinary Medicinal Product CZ, DE, IT, AT, BE, NL, LUX : Kesium 500 mg / 125 mg Chewable tablets for dogs DK, FI, SE: Kesium vet 500 mg / 125 mg Chewable tablets for dogs UK, IE, FR, EL, PL, HU, RO,
More informationPatients. Excludes paediatrics, neonates.
Full title of guideline Author Division & Speciality Scope Gentamicin Prescribing Guideline For Adult Patients Annette Clarkson, Specialist Clinical Pharmacist Antimicrobials and Infection Control All
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrocare 50 mg/ml Solution for Injection for Cattle, Pigs, Dogs and Cats (UK, IE, FR) Floxadil 50 mg/ml Solution for Injection
More informationSuitability of Antibiotic Treatment for CAP (CAPTIME) The duration of antibiotic treatment in community acquired pneumonia (CAP)
STUDY PROTOCOL Suitability of Antibiotic Treatment for CAP (CAPTIME) Purpose The duration of antibiotic treatment in community acquired pneumonia (CAP) lasts about 9 10 days, and is determined empirically.
More informationClinical Policy: Clindamycin (Cleocin) Reference Number: CP.HNMC.08 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC
Clinical Policy: (Cleocin) Reference Number: CP.HNMC.08 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy
More informationECHO: Management of URIs. Charles Krasner, M.D. Sierra NV Veterans Affairs Hospital University of NV, Reno School of Medicine October 16, 2018
ECHO: Management of URIs Charles Krasner, M.D. Sierra NV Veterans Affairs Hospital University of NV, Reno School of Medicine October 16, 2018 Infectious causes of URIs change over time Most ARIs are viral
More informationSynopsis. Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets
Synopsis Name of the sponsor Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets Name of active ingredient Title of the study Study
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Nuzyra) Reference Number: CP.PMN.## Effective Date: 11.20.18 Last Review Date: 02.19 Line of Business: Commercial, TBD HIM*, Medicaid Coding Implications Revision Log See Important Reminder
More informationPackage leaflet: Information for the patient. Co-amoxiclav 250 mg/125 mg film-coated tablets Amoxicillin/clavulanic acid
Package leaflet: Information for the patient Co-amoxiclav 250 mg/125 mg film-coated tablets Amoxicillin/clavulanic acid Read all of this leaflet carefully before you start taking this medicine because
More informationMEDICATION GUIDE FLOXIN [Flox in] (ofloxacin)
MEDICATION GUIDE FLOXIN [Flox in] (ofloxacin) Read the Medication Guide that comes with FLOXIN before you start taking it and each time you get a refill. There may be new information. This Medication Guide
More informationStaphylex Flucloxacillin (sodium)
Staphylex Flucloxacillin (sodium) PRODUCT INFORMATION Name of the Medicine Flucloxacillin sodium is the sodium salt of 3-(2'-chloro-6'-fluorophenyl)-5-methyl-4-isoxazolylpenicillin monohydrate. Structural
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Community Acquired 1) Is it pneumonia? ie new symptoms and signs of a lower respiratory
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fluclon 250 mg Capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 250mg of flucloxacillin as flucloxacillin sodium.
More informationPACKAGE LEAFLET Page 1 of 6
PACKAGE LEAFLET Page 1 of 6 Package leaflet: Information for the patient Desloratadine Mylan 5 mg film-coated tablets desloratadine Read all of this leaflet carefully before you start taking this medicine
More informationAmoxicillin 500 Mg Dosage For Dogs
Amoxicillin 500 Mg Dosage For Dogs amoxicillin cost canada amoxicillin 500mg twice a day for 7 days amoxicillin 500 dosage amoxicillin 250mg 5ml dosage for babies amoxicillin 90 mg kg day amoxicillin mg
More informationAmoxicillin clavulanic acid spectrum
Cari untuk: Cari Cari Amoxicillin clavulanic acid spectrum 14-8-2017 Amoxicillin and clavulanate potassium (AMC), also known as augmentin, is an antibiotic used to treat bacterial infections. AMC is available
More informationPneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC
Pneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC APPROVED BY: Policy and Guidelines Committee TRUST REFERENCE: B9/2009 AWP Ref: AWP61 Date (approved): July 2008 REVIEW
More informationPerichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV
Empiric Antibiotics for Pediatric Infections Seen in ED NOTE: Choice of empiric antibiotic therapy must take into account local pathogen frequency and resistance patterns, individual patient characteristics,
More informationSource: Portland State University Population Research Center (
Methicillin Resistant Staphylococcus aureus (MRSA) Surveillance Report 2010 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Health Authority Updated:
More informationStudy of First Line Antibiotics in Lower Respiratory Tract Infections in Children
IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS) e-issn:2278-3008, p-issn:239-7676. Volume 2, Issue 4 Ver. VI (Jul Aug 207), PP 47-55 www.iosrjournals.org Study of First Line Antibiotics in
More informationFDA-Approved Medication Guide MEDICATION GUIDE Moxifloxacin Hydrochloride Tablets (mox'' i flox' a sin hye'' droe klor' ide) Rx only
FDA-Approved Medication Guide MEDICATION GUIDE Moxifloxacin Hydrochloride Tablets (mox'' i flox' a sin hye'' droe klor' ide) Rx only Read the Medication Guide that comes with moxifloxacin hydrochloride
More informationB. PACKAGE LEAFLET 1
B. PACKAGE LEAFLET 1 PACKAGE LEAFLET NICILAN 400 mg/100 mg tablets for dogs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
More informationRandomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis
Randomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis Steve SM Wong Alice Ho Miu Ling Nethersole Hospital Background PD peritonitis is a major cause of PD
More informationAntimicrobial Stewardship in the Long Term Care and Outpatient Settings. Carlos Reyes Sacin, MD, AAHIVS
Antimicrobial Stewardship in the Long Term Care and Outpatient Settings Carlos Reyes Sacin, MD, AAHIVS Disclosure Speaker and consultant in HIV medicine for Gilead and Jansen Pharmaceuticals Objectives
More informationPharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J
Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J Record Status This is a critical abstract of an economic evaluation
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Pneumonia Community Acquired Pneumonia 1) Is it pneumonia? ie new symptoms and signs of
More informationINFECTIONS IN CHILDREN-ANTIMICROBIAL MANAGEMENT
INFECTIONS IN CHILDREN-ANTIMICROBIAL MANAGEMENT Name & Title Of Authors: Dr M Milupi, Consultant Microbiologist Dr N Rao,Consultant Paediatrician Dr V Desai Consultant Paediatrician Date Revised: DEC 2015
More informationCEPHALEXIN CAPSULES USP Rx only
CEPHALEXIN CAPSULES USP Rx only To reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin capsules and other antibacterial drugs, cephalexin capsules should be used
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationIs Amoxicillin 500 Mg Good For Strep Throat
Is Amoxicillin 500 Mg Good For Strep Throat amoxicillin 250 mg dosage for dogs amoxicillin 1000 mg dosage amoxicillin 500mg dosage ear infection amoxicillin 500mg dosage for cats amoxicillin trihydrate
More information